Objective: The DNA repair capacity (DRC) of tumor cells is an important contributor to resistance to radiation and platinumbased drugs. Because DRC may be affected by tumor cell metabolism, we measured DRC in lymphocytes from patients with nonesmall-cell lung cancer (NSCLC) and compared the findings with the maximum standardized uptake value (SUV max ) on 18 Ffluorodeoxyglucose positron emission tomography (FDG PET) after (chemo)radiation therapy. Methods: This study included 151 patients with stage IA-IV NSCLC who had FDG PET at a single institution and donated blood samples before chemotherapy. We assessed the correlation of DRC, measured in peripheral T lymphocytes by a host-cell reactivation assay with SUV max and their associations with overall survival (OS) time by hazards ratios calculated with a Cox proportional hazards regression model. Results: SUV max of the primary tumor at diagnosis was inversely associated with lymphocyte DRC (r ¼ À0.175, P ¼ 0.032), particularly among patients with advanced disease (r ¼ À0.218, P ¼ 0.015). However, DSUV max of primary tumor was not significantly associated with DRC (r ¼ 0.005, P ¼ 0.968). SUV max of regional lymph nodes at diagnosis (r ¼ À0.307, P ¼ 0.0008) and after (chemo)radiation treatment (r ¼ À0.329, P ¼ 0.034) and SUV max of the primary tumor after (chemo)radiation treatment (r ¼ À0.253, P ¼ 0.045) were also inversely associated with OS time. Conclusion: DRC was inversely associated with primary tumor SUV max before treatment but not with DSUV max after (chemo)radiation.
Introduction
Treatment for nonesmall-cell lung cancer (NSCLC) includes chemotherapy, radiotherapy, and surgery, in various combinations. However, the recommended treatment for unresectable tumors is often concurrent chemoradiotherapy. 1 Glucose uptake by tumors, measured with the radiotracer 18 F-fluorodeoxyglucose on positron emission tomography (FDG PET), provides an assessment of the metabolic activity of tumors in vivo. Cancers such as NSCLC can be detected by elevated glucose uptake on PET images. 2 This uptake can be quantified on PET images as standardized uptake values (SUVs), which are directly proportional to the proliferative activity of the tumor. 3 Changes in SUV for primary tumors and peripheral lymph nodes before and after treatment can be useful for assessing whether a tumor has responded to therapy.
Exposure of tumors to radiation generates doublestrand breaks in cellular DNA, which are lethal, if they cannot be adequately repaired. 4 Thus, a poor response to radiotherapy could reflect efficient DNA repair capacity (DRC) of tumor cells. The SUV, which also represents tumor cell activity, could be affected by the DRC as well. In this study, we evaluated potential correlations between DRC, measured in peripheral lymphocytes with a host-cell reactivation assay, but presumably inherited as a host factor, and the maximum SUV (SUV max ) of the primary tumor and regional lymph nodes on PET scans obtained before and after radiation, with or without concurrent chemotherapy, for unresectable NSCLC.
Materials and methods

Patient selection criteria
Patients were selected from a database of patients who had received radiation !60 Gy delivered by intensity-modulated radiation therapy (IMRT) or passively scattered proton therapy (PSPT), with or without chemotherapy, as definitive treatment for stage IA-IV NSCLC from January 2002 through April 2009 in the Department of Radiation Oncology at MD Anderson Cancer Center. The 151 selected patients all had PET scans of primary tumors and regional lymph nodes before treatment; some had PET scans after treatment, and all had information on DRC available through the same database.
SUV measurement
Primary tumor and regional lymph node SUV measurements were obtained as described previously. 5 The maximum values were calculated as SUV ¼ tissue radioactivity concentration (mCi/ml)/[injected dose (mCi)/body weight (kg)]. All measured SUVs were described as SUV max , which was obtained from the maximum tumor uptake in a 1-pixel region of interest. Use of SUV max is an effective way of reducing partial volume effects 6 and standardizing data collection. Changes between pretreatment SUV (SUV pre ) and post-treatment SUV (SUV post ) were calculated as DSUV ¼ SUV post e SUV pre . In patients who had chemotherapy, the SUV pre data were derived from PET images obtained before the start of chemotherapy. SUV post data were derived from PET images obtained at the closest time after radiation therapy (RT) had been completed.
DRC measurement
Blood samples (20 ml) had been collected in 2 green top heparin vacutainer tubes. Peripheral lymphocytes were then isolated within one day using Ficoll approach and cryopreserved in liquid nitrogen. At least 6 Â 10 6 lymphocytes were thawed and cultured in duplicates for 3 days before transfection. 250 ng plasmid was used for each transfection. Finally, DRC was measured in peripheral lymphocytes with a host-cell reactivation assay. 7, 8 The assay used benzo(a)pyrene diol epoxide (BPDE), an ultimate metabolite of polycyclic aromatic hydrocarbon in tobacco smoke, to damage non-replicating recombinant plasmids containing a chloramphenicol acetyltransferase (CAT) reporter gene, which had been transfected in parallel with undamaged plasmids by the diethylaminoethyl-dextran method 9 into cultured T-lymphocytes stimulated by phytohemagglutinin.
Cultures were then incubated for 40 hours after transfection to allow the repair and expression of the CAT reporter.
Because unrepaired DNA adducts can block CAT transcription, measurable CAT activity in the transfected cells was proportional to the ability of the cells to remove BPDE-induced DNA adducts from the plasmids. CAT 
Statistical analysis
Data were analyzed with SAS version 9.3 (SAS Institute, Cary, NC, USA). We used one-way frequency procedures for discrete variables and univariate analysis of the distributions of continuous variables such as age, DRC, and SUV. Student's t tests were used to compare differences in continuous variables between two groups for each categorized discrete variable. Spearman's rank correlation coefficients and Pearson correlation coefficients were used to express correlations between SUV and DRC or overall survival (OS) time. We used the Cox proportional hazards model to evaluate potential effects of DRC and SUV on OS, calculated as hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). Survival time was calculated from the date of diagnosis until the date of death or last follow-up. All HRs were adjusted for age, gender, race and stage. KaplaneMeier analysis was used to visualize the effect of SUV on the cumulative probability of OS, and log-rank tests were used to compare differences in survival time of the various groups. All reported P values were two-sided, with P < 0.05 as the significance level.
Results
Characteristics of the 151 patients in this analysis are shown in Table 1 . The dataset consisted of 72 men and 79 women, with a median age of 62 years (range, 29e87 years); 57.6% (87/151) were <65 years old. One hundred and ten patients (72.8%) were nonHispanic white. Eighty-six patients (57.0%) had adenocarcinoma, followed by squamous cell carcinoma (32/151, 21.2%), and others including not-otherwise- Table 1) .
The distribution of continuous variables and the correlations between SUV characteristics, DRC, and OS time are shown in Table 2 We further assessed correlations between the SUV max and DRC expressed as Spearman's rank correlation coefficients ( Table 2 ). The SUV max of the primary tumor at diagnosis correlated significantly with a decrease in DRC (r ¼ À0.175, P ¼ 0.032) in all 151 patients, and this association was more pronounced for the 125 patients with advanced disease (r ¼ À0.218, P ¼ 0.015) than for the 26 patients with early disease (r ¼ 0.259, P ¼ 0.201). The SUV max of the primary tumor after radiation therapy marginally correlated with a decrease in DRC (r ¼ À0.233, P ¼ 0.066) in the 63 patients for whom this Fig. 1 also showed similar trends of correlation between DRC and SUV max of the primary tumor at diagnosis according to disease stage. Primary tumor SUV max after treatment and SUV max of regional lymph nodes at diagnosis and after treatment were also found to correlate with a decrease in OS time (r ¼ À0.253, P ¼ 0.045; r ¼ À0.307, P ¼ 0.0008 and r ¼ À0.329, P ¼ 0.034). The DSUV max of the primary tumor for the 16 patients with early-stage disease also correlated with OS time (r ¼ À0.541, P ¼ 0.030), as did SUV max of regional lymph nodes at diagnosis for the 95 patients with advanced-stage disease (r ¼ À0.275, P ¼ 0.007).
Finally, we performed survival analysis using a Cox proportional hazards regression model to evaluate the potential influence of DRC and SUV on OS, calculated as HRs and corresponding 95% CIs. Crude HRs and HRs adjusted for age, gender, race and stage (Table 3) confirmed the correlation analysis findings in that every unit increase in SUV max of the primary tumor after treatment led to a 9% increase in HR for poor OS, and every unit increase in the SUV max of the regional Table 3) . KaplaneMeier curves of OS according to the SUV max of regional nodes at diagnosis ( Fig. 2A and B ) indicate a significant difference for patients with advanced disease (P ¼ 0.017) but not for those with early-stage disease (P ¼ 0.532); on the other hand, OS according to the SUV max of the regional nodes after radiation was significantly different for the 11 patients with earlystage disease (P ¼ 0.033) and was borderline different for the 31 patients with advanced-stage disease (P ¼ 0.060) (Fig. 2C and D) .
Discussion
We previously reported that large decreases in SUV max after definitive radiation were associated with better survival for 49 patients with locally advanced (stage III) NSCLC; more specifically, having a high post-treatment SUV max (in either the primary tumor or the lymph nodes) was associated with higher risks of death and disease recurrence. 5 In another study of 84 patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy, we found that SUV max after treatment predicted local recurrence-free survival and that SUV max both before and after treatment predicted distant metastasis-free survival, progression-free survival, and OS. 10 In the present analysis of a larger number of patients (151), most (82.8%) of whom had stage IIIeIV disease, OS was significantly associated with SUV max of the primary tumor after treatment and with SUV max of the regional lymph nodes, both at diagnosis and after treatment.
FDG-PET is useful for visualizing cellular metabolism. Compared with normal cells, tumor cells usually show higher glucose metabolism, 11 which is important for deoxynucleoside triphosphate (dNTP) and DNA synthesis. Elevated uptake of FDG as seen on PET scans may be biologically correlated with tumor metastatic potential, aggressiveness, proliferation or hypoxia, and angiogenesis.
12e14 Therapy with ionizing radiation controls cell growth via DNA damage, mainly DNA double-strand breaks. In the present study, the DRC we measured reflected nucleotide excision repair, not double-strand break repairs, and thus was not correlated with the effects of radiation treatment. However, DRC measured in peripheral blood lymphocytes was significantly inversely associated with SUV max of the primary tumor at diagnosis in patients with stage IIIeIV disease. Genomic stability reflects a balance between DNA damage and repair; a cell's nucleotide excision repair capacity is essential to this process. In tumor cells, this balance is broken, leading to their uncontrolled growth. From a biological standpoint, it is plausible that tumor cells with poor DRC would show elevated metabolism, increased proliferation, and high SUV max . We reported previously that optimal DRC in peripheral lymphocytes was associated with poor survival in 591 patients with NSCLC after platinum-based chemotherapy. 7 FDG uptake could reflect levels of proteins involved in chemo-resistance within tumor cells, and thus SUV max could be useful for assessing the effectiveness of platinum-based chemotherapy. 15 To our knowledge, very few studies have investigated the correlation between DNA repair and SUV max . A Japanese research group investigated the relationship between the expression level of ERCC1 (a core protein in nucleotide excision repair) and SUV max in 38 patients with thymoma and reported a statistically significant correlation (Spearman r ¼ 0.554). 16 However, the finding from a Korean research group did not support that correlation in 313 NSCLC patients. 17 Therefore, more rigorous investigation of potential relationships between FDG uptake and DRC is warranted.
In conclusion, our findings from the present study confirmed that SUV max , especially that of primary tumors after radiation treatment and that of regional lymph nodes before and after radiation treatment, was significantly associated with OS in patients with NSCLC. SUV max of primary tumors before treatment was significantly inversely associated with cellular DRC, as evaluated in peripheral lymphocytes. Therefore, assessing the DRC in surrogate tissues may provide guidance for the choice of chemotherapeutic agents or other treatment modalities in the future.
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